

**Compartmentalized cAMP Responses to Prostaglandin
EP₂ Receptor Activation in Human Airway Smooth Muscle Cells**

¹Shailesh R. Agarwal, ¹Kathryn Miyashiro, ¹Htun Latt,

²Rennolds S. Ostrom, and ¹Robert D. Harvey

¹Department of Pharmacology,

University of Nevada Reno School of Medicine, Reno, NV 89557

and

²Department of Biomedical and Pharmaceutical Sciences,

Chapman University School of Pharmacy, Irvine, CA 92618

Running Title: cAMP Compartmentation in Human Airway Smooth Muscle Cells

Address for Correspondence: Robert D. Harvey

Department of Pharmacology

University of Nevada, Reno

1664 N. Virginia Street, MS 573

Reno, NV 89509

email: rdharvey@unr.edu

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.13904

Abstract

Background and Purpose

Previous studies indicate that prostaglandin EP₂ receptors (EP₂Rs) selectively couple to adenylyl cyclase type 2 (AC2) in non-lipid raft domains of airway smooth muscle (ASM) cells, where they regulate specific cAMP-dependent responses. The goal of the present study was to identify the cellular microdomains where EP₂Rs stimulate cAMP production.

Experimental Approach

FRET-based cAMP biosensors were targeted to different subcellular locations of primary human ASM cells. The Epac2-camps biosensor, which expresses throughout the cell, was used to measure bulk cytoplasmic responses. Epac2-MyrPalm and Epac2-CAAX were used to measure responses associated with lipid raft and non-raft regions of the plasma membrane, respectively. Epac2-NLS was used to monitor responses at the nucleus.

Key Results

Activation of AC with forskolin or β_2 -adrenergic receptors (β_2 ARs) with isoproterenol increased cAMP in all subcellular locations. Activation of EP₂Rs with butaprost produced cAMP responses that were most readily detected by the non-raft and nuclear sensors, but only weakly detected by the cytosolic sensor and not detected at all by the lipid raft sensor. Exposure to rolipram, a phosphodiesterase type 4 (PDE4) inhibitor, unmasked the ability of EP₂Rs to increase cAMP levels associated with lipid raft domains. Overexpression of AC2 selectively increased EP₂R-stimulated production of cAMP in non-raft membrane domains.

Conclusions and Implications

EP₂R activation of AC2 leads to cAMP production in non-raft and nuclear compartments of human ASMs, while β_2 AR signaling is broadly detected across microdomains. Activity of PDE4 appears to play a role in maintaining the integrity of compartmentalized EP₂R responses in these cells.

Non-standard Abbreviations

AKAP – A kinase anchoring protein

AC2 – adenylyl cyclase type 2

AC6 – adenylyl cyclase type 6

ASM – airway smooth muscle

β_2 AR – beta-2 adrenergic receptor

But – butaprost

CREB – cAMP response element binding protein

Epac2-camps – exchange protein activated by cAMP type 2 based cAMP biosensor

Epac2-CAAX – Epac2-camps biosensor with a prenylation targeting sequence

Epac2-MyrPalm – Epac2-camps biosensor with an acylation targeting sequence

Epac2-NLS – Epac2-camps biosensor with a nuclear localization signal

EP₂R – EP2 prostaglandin receptor

FSK – forskolin

IL-6 – interleukin 6

IBMX – isobutylmethylxanthine

Iso – isoproterenol

PDE – phosphodiesterase

PDE4 – phosphodiesterase type 4

Introduction

Stimulation of cAMP production regulates bronchomotor tone by causing relaxation of airway smooth muscle (ASM) cells (Pelaia et al., 2008; Noble et al., 2014).

Furthermore, disruption of cAMP signaling is believed to contribute to hyper-responsiveness to contractile stimuli, resulting in respiratory problems associated with asthma and chronic obstructive pulmonary disease (Pelaia et al., 2008).

However, cAMP regulates a number of other important cellular activities, including carbohydrate and lipid metabolism, gene expression, as well as cell growth and proliferation (Billington et al., 2013). In human ASM cells, cAMP production is linked to the activation of β_2 adrenergic receptors (β_2 ARs) as well as EP₂ prostaglandin receptors (EP₂Rs) (Bogard et al., 2011). However, these receptors do not all produce the same cAMP-dependent responses. For example, only β_2 AR activation leads to enhanced arborization (Bogard et al., 2012), a cell shape change that reflects cytoskeletal reorganization (Gros et al., 2006), while only EP₂R activation increases expression of the cytokine interleukin-6 (IL-6) (Bogard et al., 2014). This raises the question as to how a cell is able to discriminate between cAMP signals that are produced by these two types of receptors.

The current hypothesis is that β_2 ARs and EP₂Rs produce cAMP in different subcellular compartments. This is supported by the fact that these receptors are found in different membrane domains (Ostrom et al., 2001). The plasma membrane of most cells contains cholesterol and sphingomyelin rich areas referred to as lipid rafts. In ASM cells, β_2 ARs are found in lipid raft fractions associated specifically with caveolins, which are membrane bound scaffolding proteins that can contribute to the formation of caveolae. EP₂Rs, on the other hand, are excluded from lipid raft fractions of the plasma membrane. Previous studies also indicate that different cAMP dependent responses are associated with specific isoforms of adenylyl cyclase (AC). ASM cells express multiple AC isoforms, including AC2 as well as AC6 (Xu et al., 2001; Bogard et al., 2011). Furthermore, AC6 is found specifically in lipid raft fractions of the plasma membrane, while AC2 is excluded from these domains. In addition, overexpression of AC6 enhances β_2 AR production of cAMP and cAMP-dependent arborization in ASM cells (Bogard et al., 2012), whereas overexpression of AC2 enhances EP₂R production of cAMP as well as cAMP-dependent expression of IL-6 (Bogard et al., 2014).

The evidence described above is consistent with the idea that receptor-dependent production of cAMP is spatially restricted to subcellular locations associated with different membrane microdomains. They also show that distinct AC isoforms exist in these separate domains and couple specifically to co-localized receptors. The purpose of this study was to directly test this hypothesis by measuring cAMP activity in live, primary human ASM cells using the genetically encoded FRET-based biosensor Epac2-camps targeted to different subcellular locations. Epac2-camps consists of a cAMP binding domain from the type 2 exchange protein activated by cAMP, to which EYFP has been added to the N-terminus and ECFP to the C-terminus. Binding of cAMP causes a conformational change resulting in a loss of energy transfer between the two fluorophores that can be detected as an increase in the ECFP/EYFP fluorescence ratio. Epac2-camps itself is a probe that lacks any targeting sequences, and was used to measure cAMP responses in the bulk cytoplasmic compartment of the cell (Nikolaev et al., 2004). Addition of either an acylation (Epac2-MyrPalm) or prenylation (Epac2-CAAX) sequence was used to target the probe to lipid raft and non-lipid raft domains of the plasma membrane, so that we could measure cAMP responses associated with those subcellular locations (Agarwal et al., 2014). We also measured responses using Epac2-NLS, which is targeted to the nucleus of the cell (DiPilato et al., 2004).

Our results demonstrate that stimulation of β_2 ARs and EP₂Rs results in production of cAMP in distinctly different subcellular locations in primary human ASM cells. While β_2 ARs produce cAMP that is detected uniformly throughout all sites examined, EP₂Rs have the greatest effect on cAMP production in subcellular locations associated with non-lipid raft domains of the plasma membrane as well as the nucleus.

Methods

Cell Culture. Human ASM cells were provided by Dr. Raymond Penn (Thomas Jefferson University). Cells were derived from human tracheae and primary bronchi as previously described and used between passage 6 and 9 (Yan et al., 2011). Experiments were conducted using multiple samples of primary cells derived from different patients. Cells were maintained in Ham's F12 nutrient mixture

supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin. For FRET and confocal microscopy experiments, cells were plated on 35 mm glass-bottom fluorodishes (World Precision Instruments, Inc.). Cells were transduced with adenovirus constructs containing Epac2-based cAMP biosensors for 48 hours. For AC overexpression experiments, adenoviral constructs expressing AC2 were used to transduce cells; a viral titer previously shown to produce >90% transduction was used (Bogard et al., 2011). All experiments were conducted at room temperature.

FRET biosensor construction. The Epac2-camps, Epac2-MyrPalm, and Epac2-CAAX biosensors used in the present study have been previously characterized (Nikolaev et al., 2004; Agarwal et al., 2014). For nuclear targeting, a nuclear localization signal (NLS), PKKKRKVEDA, was added to the C-terminus of Epac2-camps probe (DiPilato et al., 2004). In vitro calibration of Epac2-NLS (supplemental figure S1) was performed as described previously (Agarwal et al., 2014). The EC₅₀ and Hill coefficient for cAMP activation of each of the probes used in this study are listed in supplemental table 1.

FRET microscopy. Live cell imaging experiments were conducted using human ASM cells bathed in the following solution (in mM): NaCl 137, KCl 5.4, MgCl₂ 0.5, CaCl₂ 1.0, NaH₂PO₄ 0.33, glucose 5.5, and HEPES 5 (pH 7.4). A plastic insert (Warner Instruments) was used to reduce the total fluid volume of the fluorodish to ~200 µl, and drug containing solutions were introduced using a gravity fed perfusion system at a rate of ~1 ml/min. FRET imaging was conducted using an Olympus IX71 inverted microscope equipped with an Hamamatsu OrcaD2 dual chip CCD camera and HCAImage data acquisition and analysis software (Hamamatsu Photonics, Ltd.), as described previously (Agarwal et al., 2014). Changes in cAMP activity were defined as the change in background and bleed-through corrected ECFP/EYFP fluorescence intensity ratio (ΔR) relative to the baseline ratio (R_0) measured in a specified region of interest. FRET ratios were measured once every 10 seconds. A control period of at least 5 min was recorded prior to the application of any drug in order to allow the baseline to stabilize. Responses were calculated relative to the average baseline ratio measured over the 30 s period immediately preceding the application of drugs.

To control for variations in the absolute size of responses, these values were then normalized to the magnitude of the maximal probe response observed in the same cell following exposure to saturating concentrations of the non-specific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) plus the direct AC activator forskolin or the β AR agonist isoproterenol. For Epac2-camps, Epac2-MyrPalm, and Epac2.CAAX, FRET responses were measured using a circular region of interest (ROI) approximately 5 μ m in diameter placed over a cytoplasmic region of the cell, being sure to avoid the nucleus. Consistent with the results of Billington et al. (2008), results obtained using ROIs placed at different locations did not affect the results. For cells expressing Epac2-NLS, the ROI was drawn around the entire nucleus.

Confocal microscopy. Confocal imaging was performed using an Olympus Fluoview 1000 confocal microscope with an oil immersion objective (60x, 1.42 NA). The confocal aperture was fixed at 1 Airy unit. Images were captured at 1024 x 1024 pixels with a 20 μ s/pixel dwell time and 2x zoom in raster scan mode using a laser power of 5-10%. EYFP in cells expressing the different biosensors was excited using the 515 nm line of an argon laser and the fluorescence images were captured using a BA535-565 emission filter. Images were stored in tiff file format. The brightness and contrast of these images were adjusted in ImageJ software for presentation purposes.

Materials. Rolipram was obtained from Tocris Bioscience. Ham's F12 medium, penicillin, streptomycin, and fetal bovine serum were purchased from Life Technologies. All other reagents were purchased from Sigma-Aldrich. Isoproterenol and IBMX containing solutions were prepared fresh daily. Forskolin and butaprost containing solutions were prepared from frozen aliquots.

Statistics. All data are expressed as the mean $\pm$ SEM of the indicated number of experiments conducted using individual cells (n). Statistical significance ($p < 0.05$) was determined by Student's t-test or one way ANOVA with Holm-Sidak post-hoc analysis to identify significant outliers, where appropriate, using SigmaPlot (Systat Software, Inc.).

Nomenclature of Targets and Ligands. Key protein targets and ligands in this article are hyperlinked to corresponding entries in

<http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a; Alexander et al., 2015b).

Results

In order to monitor changes in cAMP levels associated with specific subcellular locations, we employed genetically-encoded Epac2-based biosensors with or without different targeting sequences (DiPilato et al., 2004; Agarwal et al., 2014). When expressed in human ASM cells, we observed distinct patterns of expression for each of these probes (figure 1A). As expected, Epac2-camps, the probe without any targeting sequence, exhibited diffuse fluorescence throughout the cytosol. Epac2-MyrPalm and Epac2-CAAX, which are targeted to lipid raft and non-raft membrane domains, respectively (Zacharias et al., 2002; Agarwal et al., 2014), were found primarily in the plasma membrane. However, these two probes exhibited distinctly different expression patterns. Wide field images of Epac2-MyrPalm expressing cells revealed that this probe is expressed uniformly throughout the surface membrane of these cells. However, the Epac2-CAAX probe appears to be concentrated more around the nucleus, suggesting an association between non-raft domains of the plasma membrane and the perinuclear space (figure 1B, left hand panels). In cells expressing Epac2-NLS, a highly localized nuclear fluorescence pattern was distinctly visible. These results indicate that each of our cAMP biosensors is targeted to a distinctly different subcellular location.

Next, we conducted experiments to verify that these probes were able to respond to changes in cAMP levels. Exposure to forskolin (10 μ M), to directly activate AC activity, in combination with IBMX (100 μ M), a non-specific inhibitor of phosphodiesterase (PDE) activity, was used to produce a saturating cAMP response. Comparing the left and right hand panels of figure 1B, there was no obvious change in the distribution pattern of the probes following stimulation. However, the change in activity was readily detectible as a change in the ECFP/EYFP fluorescence ratio illustrated as pseudocolor images in figure 1C. Interestingly, the time course experiments illustrated in figure 2 demonstrate that

exposure to 100 μ M IBMX alone, a concentration that should maximally inhibit most PDE isoforms, produced responses that were only 16 to 26% of that observed following maximal activation of each probe upon subsequent addition of 10 μ M forskolin. These results suggest that under basal conditions, total PDE activity is similar in all four locations. They also suggest that basal AC activity in these locations is low. Consistent with this conclusion, exposure to 100 μ M MDL-12,330A, an AC inhibitor, did not produce a significant decrease in the baseline FRET responses detected by any of our probes (see supplemental figure 2). This suggests that basal levels of cAMP are below the threshold for detection by our probes (Agarwal et al., 2014).

To determine if there are differences in the relative amount of AC activity capable of contributing to cAMP production in different subcellular locations upon stimulation, we examined the concentration dependence of the responses to forskolin (figure 3). While all four probes responded to forskolin in a concentration-dependent manner, there were differences in the apparent sensitivity. Exposure to 0.1 μ M forskolin produced responses that could be detected by every probe except Epac2-MyrPalm. Exposure to 0.3 μ M forskolin produced responses that could be detected by all four probes, although Epac2-CAAX and Epac2-NLS appeared to be the most sensitive. Exposure to 10 μ M forskolin produced responses that resulted in saturation or near saturation of all four probes. These results indicate that even though basal AC activity appears to be low, agonist stimulated AC activity is quite significant. However, there appear to be some differences in the relative amount of AC activity contributing to cAMP production in different subcellular locations.

We next compared responses to G protein coupled receptor (GPCR) activation. Exposure to the β AR agonist isoproterenol produced concentration dependent increases in cAMP activity throughout the cell (figure 4), without any apparent differences in the sensitivity of the responses detected by each of the probes. Exposure to 1 nM isoproterenol produced responses that were 22 to 42% of maximal, while 3 nM isoproterenol produced responses that were between 55 and 82% of maximal. Exposure to a maximally stimulating concentration of isoproterenol (1 μ M) produced responses that were approximately the same size as those observed in the presence of 1 μ M isoproterenol plus 100 μ M IBMX. These results

suggest that β_2 AR stimulation produces cAMP levels that are roughly equal throughout human ASM cells.

Contrary to the effects of β_2 AR stimulation, exposure to the EP₂R agonist butaprost produced a significantly different pattern of responses (figure 5). Exposure to 0.3 and 1 μ M butaprost produced concentration dependent increases in cAMP activity detected by the Epac2-CAAX and Epac2-NLS biosensors. In sharp contrast, the cytosolic biosensor Epac2-camps responded to 1 μ M but not 0.3 μ M butaprost, and the lipid raft targeted probe Epac2-MyrPalm did not respond to either concentration of butaprost. These results suggest that EP₂R stimulation elicits a localized increase in cAMP activity in subcellular locations associated with non-raft regions of the plasma membrane. Furthermore, while the cAMP produced by these receptors is unable to reach the subcellular locations associated with lipid rafts, it is readily able to reach the nucleus.

It has previously been shown that inhibition of type 4 PDE activity (PDE4) enables EP₂R stimulation to cause arborization of ASM cells (Bogard et al., 2012). This suggests that PDE4 is involved in limiting the spread of cAMP produced by EP₂Rs. To test this hypothesis, we examined the effect of the selective PDE4 inhibitor rolipram on the cAMP responses produced by butaprost (figure 6). Exposure to 10 μ M rolipram alone had no significant effect on cAMP activity detected by any of the probes. However, the presence of rolipram did alter the response to 1 μ M butaprost, eliminating any significant difference in the magnitude of the responses detected by any of the probes. Most notable was the fact that the Epac2-MyrPalm probe was able to detect a change in cAMP activity following exposure to 1 μ M butaprost. This is in contrast to the absence of any change in cAMP activity detected by this probe when butaprost was applied in the absence of rolipram (see figure 5).

Previous studies have suggested that EP₂Rs couple specifically to AC2 in non-raft regions of the plasma membrane in ASM cells (Bogard et al., 2011; Bogard et al., 2012; Bogard et al., 2014). To examine this possibility, we compared the cAMP responses detected by the lipid raft targeted Epac2-MyrPalm and non-raft targeted Epac2-CAAX probes in ASM overexpressing AC2 (figure 7). The results demonstrate that AC2 overexpression had no effect on the inability of butaprost to

elicit a response detected by Epac2-MyrPalm. However, AC2 overexpression did significantly enhance the response to 1 μ M butaprost detected by Epac2-CAAX (figure 7D). To verify that this result was specific for EP₂R activation, we also examined the effect of AC2 overexpression on the responses to β_2 AR stimulation (figure 8). The results demonstrate the AC2 overexpression did not enhance the responses to isoproterenol detected by either Epac2-MyrPalm or Epac2-CAAX. If anything, the responses to isoproterenol measured by both of these probes were slightly decreased.

Discussion

Human ASM cells, like most cell types, express several GPCRs linked to the production of cAMP. A long-standing quandary is how these receptors, which respond to a vast array of neurohumoral signals, yield different cellular responses via the same second messenger. The results of the present study demonstrate that the segregation of signaling proteins into different membrane domains plays an important role in generating spatially localized cAMP production in human ASM cells (Bogard et al., 2011; Bogard et al., 2012; Ostrom et al., 2012; Bogard et al., 2014). Specifically, our results support the conclusion that EP₂R activation of AC2 generates a localized pool of cAMP in subcellular locations associated with non-lipid raft domains of the plasma membrane. This is based on two primary observations. First, EP₂R stimulation causes a rise in cAMP levels that are detected by the non-raft targeted Epac2-CAAX biosensor, but not the raft-anchored Epac2-MyrPalm probe (see figure 5). Second, overexpression of AC2 augments EP₂R stimulation of cAMP in non-raft domains, but not lipid raft associated domains (see figure 7), without enhancing β_2 AR responses in either location (see figure 8). These data indicate that EP₂R and β_2 AR exist in distinct microdomains and couple selectively to different AC isoforms, consistent with previous findings (Bogard et al., 2011; Bogard et al., 2012).

Previous reports indicate that activation of AC2 regulates the production of IL-6 in ASM cells (Bogard et al., 2014). IL-6 gene expression involves protein kinase A (PKA) activation of the cAMP response element binding protein (CREB), and subsequent enhancement of gene transcription (Yamamoto et al., 1988). It is believed that the binding of cAMP to PKA releases the catalytic subunit of the

kinase, allowing it to translocate from cytoplasm into the nucleus where it phosphorylates CREB (Harootunian et al., 1993; Altarejos & Montminy, 2011). If this is the case, then activation of PKA anywhere in the cell might be expected to equally regulate all CRE-containing gene promoters. However, the fact that AC6-derived cAMP production does not affect the expression of IL-6, and AC2-derived cAMP production does not increase expression of somatostatin, another CRE-regulated gene (Bogard et al., 2014), suggests that this is not the case. It implies that the subcellular location of cAMP production is important for how the nucleus interprets such signals. Consistent with this idea, EP₂R stimulation was also able to produce significant changes in cAMP that could be detected by our nuclear targeted biosensor Epac2-NLS. In fact, EP₂R stimulation produced changes in cAMP at the nucleus that appeared to be greater than those detected near the plasma membrane by Epac2-CAAX (see figure 5). The explanation for this difference is not immediately obvious, but may be due to EP₂Rs being expressed in nuclear membranes. It is interesting to note that the probe targeted to non-lipid raft domains of the plasma membrane appears to concentrate around the nucleus (see figure 1B).

β₂AR activation was also able to produce changes in cAMP that were detected by the nuclear probe, indicating that signals emanating from lipid raft domains are able to reach the nucleus as well. Thus, a complex model of how cAMP signals convey information to the nucleus is needed. It may be that cAMP signals originating from different locations activate different arrays of PKA phosphorylated signaling proteins, such that the resulting information flowing to the nucleus is unique for each locale. Future studies are needed to determine whether the subcellular pattern of PKA activation correlates directly with that of cAMP production. A kinase anchoring proteins (AKAPs) could fulfill some of the role in targeting PKA action in specific signaling complexes. AKAPs shape β₂AR responses in human ASMs by regulating receptor and PDE phosphorylation to create negative feedback (Horvat et al., 2012; Ostrom et al., 2012). Different AKAPs bind specific AC isoforms, creating the likelihood that these proteins organize downstream elements into signaling complexes (Efendiev & Dessauer, 2011).

It has also been reported that cAMP produced by the EP₂R and AC2 in non-raft domains are not able to regulate ASM cell arborization (a response robustly enhanced by β₂AR and AC6) unless a PDE4 inhibitor is added (Bogard et al., 2012).

Again, differences in the subcellular location of cAMP production are likely to be involved in explaining these observations. The present results demonstrate that β_2 AR stimulation was able to increase cAMP to similar levels in all locations examined (see figure 4). By contrast, EP₂Rs failed to produce a detectable change in cAMP in locations associated with lipid raft domains of the plasma membrane and more weakly produced cAMP detected by the cytosolic sensor (figure 5). Because the non-raft targeted probe was concentrated centrally, in the membrane around the nucleus, whereas the lipid-raft targeted probe was found more uniformly throughout the plasma membrane, it is conceivable that cAMP produced in the periphery of the cell may be more important in regulating cell shape. IBMX did not have drastically different effects on cAMP levels detected by the Epac2-CAAX sensor. However, overexpression of AC2 increased cAMP signaling in the non-raft domain but did not produce “spillover” into the lipid raft domain (as sensed by Epac2-MyrPalm), implying that cAMP diffusion from the EP₂R-AC2 complex in the non-raft domain is more restricted.

Phosphodiesterase activity is thought to play an essential role in compartmentation of cAMP responses, and PDE4 is believed to be the predominant isoform regulating cAMP activity in human ASM cells (Conti et al., 2003; Houslay & Adams, 2003; Méhats et al., 2003; Billington et al., 2008; Nino et al., 2009; Xin et al., 2015). In fact, previous studies found that inhibition of PDE4 unmask the ability of AC2-mediated cAMP production to cause arborization of ASM cells (Bogard et al., 2012). Consistent with this observation, we found that inhibition of PDE4 activity was also able to significantly increase the diffusion of EP₂R mediated cAMP production. Most notable was the fact that inhibition of PDE4 revealed a cAMP response previously undetectable by Epac2-MyrPalm in subcellular locations associated with lipid rafts (see figure 6). This could be explained if PDE4 activity is more concentrated in subcellular locations associated with lipid rafts, limiting the ability of cAMP produced in non-raft domains from diffusing in and reaching significant levels. If true, then the increase in PDE4D activity that occurs with asthma (Trian et al., 2011) might be expected to limit cAMP signaling associated specifically with these microdomains.

It is worth noting, however, that IBMX, which inhibits most PDE isoforms, produced a small, but significant change in basal cAMP activity in all subcellular

locations (see figure 2). This indicates that all microdomains contain some PDE activity. However, if IBMX had inhibited all PDE activity, we would have expected to see saturating responses. The fact that we did not suggests that there must be some IBMX-insensitive PDE activity in these cells. Furthermore, because inhibition of PDE4 activity alone had no significant effect (see figure 6), this suggests that human ASM cells also express IBMX-sensitive PDE isoforms other than just PDE4. Modeling studies have also suggested that while PDE activity is essential, it alone cannot explain cAMP compartmentation (Saucerman et al., 2014). In addition to segregation of receptors and ACs in distinct physical locations, other contributing factors are likely to include slow diffusion of cAMP that is independent of PDE activity (Agarwal et al., 2016) as well as restricted spaces defined by cell morphology (Feinstein et al., 2012; Yang et al., 2016). As a result, once cAMP is produced by a particular AC isoform in a specific location, that signal is not freely diffusible so these distinct signals can regulate different downstream responses by the cell.

Smooth muscle cells can undergo phenotypic changes with time in culture. However, it has been reported that cAMP responses are maintained in human ASM cells well beyond the passage number used in the present study (Stewart et al., 1997). Furthermore, the receptor specific cAMP responses we observed are consistent with previous results obtained using similar cells (Bogard et al., 2011; Bogard et al., 2012; Bogard et al., 2014).

In conclusion, our study provides the first direct evidence for the generation of receptor-mediated production of spatially localized pools of cAMP within different microdomains of primary human ASM cells. EP₂R-stimulated cAMP signaling is clearly more restricted than β_2 AR-stimulated cAMP signaling in near-membrane regions even though both receptors elicit cAMP signaling at the nucleus. The results add to our understanding of how this common second messenger may elicit distinct receptor-specific functional responses in these cells.

Author Contributions

RDH and RSO conceived and designed the experiments. KM, SRA, and HL conducted the experiments and analyzed the data. RDH, SRA, and RSO were involved in interpretation of the results. SRA and RDH drafted the manuscript. RSO

revised the manuscript for intellectual content. All authors critically reviewed the content and approved the final version of the manuscript.

Acknowledgements

The authors thank Dr. Raymond Penn and Dr. Tonio Pera, Thomas Jefferson University, for supplying the human ASM cells. This work was supported by National Institutes of Health Grants R01 GM107094 (RSO) and R01 GM101928 (RDH).

Conflicts of Interest

None

References

Agarwal SR, Clancy CE, & Harvey RD (2016) Mechanisms restricting diffusion of intracellular cAMP. *Sci Rep* 6:10.1038/srep19577.

Agarwal SR, Yang PC, Rice M, Singer CA, Nikolaev VO, Lohse MJ, *et al.* (2014) Role of membrane microdomains in compartmentation of cAMP signaling. *PLoS One* 9:e95835.

Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, *et al.* (2015a) The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. *Br J Pharmacol* 172:5744-5869.

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, *et al.* (2015b) The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. *Br J Pharmacol* 172:6024-6109.

Altarejos JY, & Montminy M (2011) CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* 12:141-151.

Billington CK, Le Jeune IR, Young KW, & Hall IP (2008) A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. *Am J Respir Cell Mol Biol* 38:1-7.

Billington CK, Ojo OO, Penn RB, & Ito S (2013) cAMP regulation of airway smooth muscle function. *Pulm Pharmacol Ther* 26:112-120.

Bogard AS, Adris P, & Ostrom RS (2012) Adenylyl cyclase 2 selectively couples to E prostanoid type 2 receptors, whereas adenylyl cyclase 3 is not receptor-regulated in airway smooth muscle. *J Pharmacol Exp Ther* 342:586-595.

Bogard AS, Birg AV, & Ostrom RS (2014) Non-raft adenylyl cyclase 2 defines a cAMP signaling compartment that selectively regulates IL-6 expression in airway smooth muscle cells: differential regulation of gene expression by AC isoforms. *Naunyn Schmiedebergs Arch Pharmacol* 387:329-339.

Bogard AS, Xu C, & Ostrom RS (2011) Human bronchial smooth muscle cells express adenylyl cyclase isoforms 2 , 4 , and 6 in distinct membrane microdomains. *J Pharmacol Exp Ther* 337:209-217.

Conti M, Richter W, Mehats C, Livera G, Park JY, & Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. *J Biol Chem* 278:5493-5496.

DiPilato LM, Cheng X, & Zhang J (2004) Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. *Proc Natl Acad Sci USA* 101:16513-16518.

Efendiev R, & Dessauer CW (2011) A kinase-anchoring proteins and adenylyl cyclase in cardiovascular physiology and pathology. *J Cardiovasc Pharmacol* 58:339-344.

Feinstein WP, Zhu B, Leavesley SJ, Sayner SL, & Rich TC (2012) Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells. *Am J Physiol Cell Physiol* 302:C839-852.

Gros R, Ding Q, Chorazyczewski J, Pickering GJ, Limbird LE, & Feldman RD (2006) Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization. *Circ Res* 99:845-852.

Harootunian AT, Adams SR, Wen W, Meinkoth JL, Taylor SS, & Tsien RY (1993) Movement of the free catalytic subunit of cAMP-dependent protein kinase into and out of the nucleus can be explained by diffusion. *Mol Biol Cell* 4:993-1002.

Horvat SJ, Deshpande DA, Yan H, Panettieri RA, Codina J, DuBose TD, Jr., *et al.* (2012) A-kinase anchoring proteins regulate compartmentalized cAMP signaling in airway smooth muscle. *FASEB J* 26:3670-3679.

Houslay MD, & Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. *Biochemical Journal* 370:1-18.

Méhats C, Jin SLCL, Wahlstrom J, Law E, Umetsu DT, & Conti M (2003) PDE4D plays a critical role in the control of airway smooth muscle contraction. *FASEB J* 17:1831-1841.

Nikolaev VO, Bunemann M, Hein L, Hannawacker A, & Lohse MJ (2004) Novel single chain cAMP sensors for receptor-induced signal propagation. *J Biol Chem* 279:37215-37218.

Nino G, Hu A, Grunstein JS, & Grunstein MM (2009) Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle. *Am J Physiol Lung Cell Mol Physiol* 297:L746-757.

Noble PB, Pascoe CD, Lan B, Ito S, Kistemaker L, Tatler AL, *et al.* (2014) Airway smooth muscle in asthma: Linking contraction and mechanotransduction to disease pathogenesis and remodelling. *Pulm Pharmacol Ther* 29:96-107.

Ostrom RS, Bogard AS, Gros R, & Feldman RD (2012) Choreographing the adenylyl cyclase signalosome: sorting out the partners and the steps. *Naunyn Schmiedebergs Arch Pharmacol* 385:5-12.

Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, & Insel PA (2001)

Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. *J Biol Chem* 276:42063-42069.

Pelaia G, Renda T, Gallelli L, Vatrella A, Busceti M, Agati S, *et al.* (2008) Molecular mechanisms underlying airway smooth muscle contraction and proliferation: Implications for asthma. *Respiratory Medicine* 102:1173-1181.

Saucerman JJ, Greenwald EC, & Polanowska-Grabowska R (2014) Mechanisms of cyclic AMP compartmentation revealed by computational models. *J Gen Physiol* 143:39-48.

Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, *et al.* (2016) The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. *Nucleic Acids Res* 44:D1054-1068.

Stewart AG, Tomlinson PR, & Wilson JW (1997) Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation. *Br J Pharmacol* 121:361-368.

Trian T, Burgess JK, Niimi K, Moir LM, Ge Q, Berger P, *et al.* (2011) beta2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D. *PLoS One* 6:e20000.

Xin W, Feinstein WP, Britain AL, Ochoa CD, Zhu B, Richter W, *et al.* (2015) Estimating the magnitude of near-membrane PDE4 activity in living cells. *Am J Physiol Cell Physiol* 309:C415-424.

Xu D, Isaacs C, Hall IP, & Emala CW (2001) Human airway smooth muscle expresses 7 isoforms of adenylyl cyclase: a dominant role for isoform V. *Am J Physiol Lung Cell Mol Physiol* 281:L832-843.

Yamamoto KK, Gonzalez GA, Biggs WH, 3rd, & Montminy MR (1988)

Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. *Nature* 334:494-498.

Yan H, Deshpande DA, Misor AM, Miles MC, Saxena H, Riemer EC, *et al.* (2011)

Anti-mitogenic effects of beta-agonists and PGE2 on airway smooth muscle are PKA dependent. *FASEB J* 25:389-397.

Yang PC, Boras BW, Jeng MT, Docken SS, Lewis TJ, McCulloch AD, *et al.* (2016) A

computational modeling and simulation approach to investigate mechanisms of subcellular cAMP compartmentation. *PLoS Comput Biol* 12:e1005005.

Zacharias DA, Violin JD, Newton AC, & Tsien RY (2002) Partitioning of lipid-modified

monomeric GFPs into membrane microdomains of live cells. *Science* 296:913-916.




Figure 1. Expression pattern of Epac2-based biosensors targeted to different subcellular locations. (A) Representative confocal images of human ASM cells expressing Epac2-MyrPalm (MyrPalm, n = 27), Epac2-CAAX (CAAX, n = 68), Epac2-NLS (NLS, n = 25), and Epac2-camps (Epac2, n = 18). **(B)** Representative wide field images (EYFP fluorescence) before (left) and after (right) stimulation of cAMP production by exposure to the adenylyl cyclase activator forskolin (FSK, 10 μ M) plus the phosphodiesterase inhibitor IBMX (100 μ M). Note, there is no obvious change in distribution of biosensor following stimulation of cAMP production. **(C)** Corresponding pseudocolor images depicting the change in ECFP/EYFP fluorescence intensity ratio before (left) and after (right) exposure to FSK plus IBMX. MyrPalm (n = 6), CAAX (n = 6), NLS (n = 9) and Epac2 (n = 8)




Figure 2. Changes in cAMP responses in different subcellular domains following phosphodiesterase inhibition. (A-D) Representative time course of changes in the magnitude of the normalized FRET response ($\Delta R/R_0$) in human airway smooth muscle cells expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS (NLS), and Epac2-camps (Epac2), under control conditions,

following exposure to 100 μ M IBMX, and IBMX plus 10 μ M forskolin (FSK). **(E)** Size of average FRET responses to 100 μ M IBMX alone normalized to the magnitude of the maximal response measured in the presence of IBMX plus FSK. There was no statistical difference ($p < 0.5$, One Way ANOVA) in the size of the responses detected by MyrPalm ($16 \pm 6.4\%$, $n = 6$), CAAX ($21 \pm 5.9\%$, $n = 6$), NLS ($26 \pm 3.0\%$, $n = 9$), and Epac2 ($20 \pm 1.1\%$, $n = 8$).




Figure 3. Changes in cAMP responses in different subcellular domains following adenylyl cyclase activation. (A-D) Representative time course of changes in the magnitude of the normalized FRET response ($\Delta R/R_0$) in cells expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS (NLS), and Epac2-camps (Epac2), under control conditions, and following exposure to 0.1

Accepted Article

μM , 0.3 μM , and 10 μM forskolin (FSK). **(E)** Size of average FRET responses to FSK. The 0.1 μM FSK response detected by MyrPalm ($0.33 \pm 5.4\%$, $n = 6$) was significantly smaller ($p = 0.032$) than that detected by CAAX ($31 \pm 10\%$, $n = 6$), but not NLS ($16 \pm 6.3\%$, $n = 6$) and Epac2 ($14 \pm 4.9\%$, $n = 8$). The 0.3 μM FSK responses detected by MyrPalm ($28 \pm 8.6\%$, $n = 6$) and Epac2 ($48 \pm 3.8\%$, $n = 7$) were significantly smaller ($p < 0.01$) than those detected by CAAX ($66 \pm 13\%$, $n = 6$) and NLS ($71 \pm 3.6\%$, $n = 14$). The 10 μM FSK responses detected by CAAX ($100 \pm 1.8\%$, $n=5$), MyrPalm (92 ± 5.0 , $n = 6$), NLS (85 ± 2.3 , $n=13$), and Epac2 (93 ± 1.3 , $n=6$), were not significantly different from one another ($p > 0.05$). Statistical significance was tested using One Way ANOVA followed by Holm-Sidak method for pairwise multiple comparisons. All responses were normalized to the maximal responses elicited by 10 μM FSK plus 100 μM IBMX.




Figure 4. Changes in cAMP responses in different subcellular domains following β -adrenergic receptor stimulation. (A-D) Representative time course of changes in the magnitude of the normalized FRET response ($\Delta R/R_0$) in cells expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS (NLS), and Epac2-camps (Epac2), under control conditions, and following exposure to 1

nM, 3 nM, and 1 μ M isoproterenol (Iso). **(E)** Size of average FRET responses to Iso. 1 nM Iso: MyrPalm, $22 \pm 5.4\%$ (n = 13); CAAX, $25 \pm 8.2\%$ (n = 9); NLS, $42 \pm 14\%$ (n = 7); and Epac2, $29 \pm 8.3\%$ (n = 7). 3 nM Iso: MyrPalm, $55 \pm 7.0\%$ (n = 13), CAAX, $57 \pm 9.4\%$ (n = 9); NLS, $82 \pm 13\%$ (n = 7); and Epac2, $59 \pm 3.9\%$ (n = 7). 1 μ M Iso: MyrPalm, $96 \pm 4.5\%$ (n = 18); CAAX, $98 \pm 5.5\%$ (n = 19); NLS, $102 \pm 6.8\%$ (n = 15); and Epac2, $84 \pm 5.2\%$ (n = 11). There were no significant differences ($p > 0.05$, One Way ANOVA) in the size of the responses to any given concentration of Iso. All responses were normalized to the maximal responses elicited by 1 μ M Iso plus 100 μ M IBMX.




Figure 5. Changes in cAMP responses in different subcellular domains following E-type prostaglandin receptor stimulation. (A-D) Representative time course of changes in the magnitude of the normalized FRET response ($\Delta R/R_0$) in cells expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS (NLS), and Epac2-camps (Epac2), under control conditions, and following exposure

to 0.3 μ M and 1 μ M butaprost (But). **(E)** Size of average FRET responses to But. The responses to 0.3 μ M But detected by MyrPalm ($-0.30 \pm 2.5\%$, $n = 11$) and Epac2 ($1.27 \pm 4.1\%$, $n = 8$) were significantly smaller ($p < 0.05$) than those detected by CAAX ($15 \pm 4.0\%$, $n = 12$) and NLS ($26 \pm 4.0\%$, $n = 7$). The response to 1 μ M But detected by MyrPalm ($2.3 \pm 4.5\%$, $n = 11$) was significantly smaller ($p < 0.05$) than the responses detected by CAAX ($24 \pm 5.7\%$, $n = 10$), NLS ($43 \pm 4.7\%$, $n = 7$), and Epac2 ($16 \pm 7.0\%$, $n = 8$). The Epac2 response was also significantly smaller than the NLS response ($p < 0.05$). Statistical significance was tested using One Way ANOVA followed by Holm-Sidak method for pairwise multiple comparisons. All responses were normalized to the maximal responses elicited by 10 μ M FSK plus 100 μ M IBMX.




Figure 6. Effect of phosphodiesterase 4 (PDE4) inhibition on cAMP responses elicited by E-type prostaglandin receptor stimulation. Representative time course of changes in the magnitude of the FRET response ($\Delta R/R_0$) in cells expressing Epac2-MyrPalm (MyrPalm), following exposure to 1 μ M butaprost (But) in the absence (**A**) or presence (**B**) of the PDE4 inhibitor rolipram (Rol, 10 μ M). (**C**) Size of average FRET responses to 10 μ M Rol or Rol plus 1 μ M But. There were no significant differences ($p > 0.05$) in the size of the responses to 1 μ M Rol detected by MyrPalm ($-6.2 \pm 4.2\%$, $n = 10$), Epac2-CAAX (CAAX; $8.9 \pm 4.9\%$, $n = 8$), Epac2-NLS (NLS; $2.9 \pm 2.2\%$, $n = 6$); and Epac2-camps (Epac2; $0.61 \pm 2.3\%$, $n = 5$). There were also no significant differences in the size of the responses to 1 μ M But in the presence of 10 μ M Rol detected by MyrPalm ($27 \pm 14\%$, $n = 7$), CAAX ($36 \pm 8.3\%$, $n = 8$), NLS ($66 \pm 5.4\%$, $n = 6$), and Epac2 ($34 \pm 12\%$, $n = 5$). Statistical significance was tested using One Way ANOVA. All responses were normalized to the maximal response elicited by 10 μ M forskolin (FSK) plus 100 μ M IBMX.




Figure 7. Effect of adenyl cyclase 2 (AC2) overexpression on cAMP responses elicited by E-type prostaglandin receptor stimulation. Representative time course of changes in the normalized FRET response ($\Delta R/R_0$) detected by Epac2-MyrPalm (MyrPalm) (**A**) and Epac2-CAAX (CAAX) (**B**) following exposure to 0.3 μ M and 1 μ M butaprost (But) in cells overexpressing AC2. (**C**) Size of average FRET responses in AC2 overexpressing (AC2 OE) cells. The size of the response to 0.3 μ M butaprost detected by MyrPalm ($-0.81 \pm 0.73\%$, $n = 5$) was significantly smaller ($p < 0.05$) than that detected by CAAX ($16 \pm 5.2\%$, $n = 9$). The size of the response to 1 μ M butaprost detected by MyrPalm ($3.3 \pm 5.7\%$, $n = 3$) was also significantly smaller ($p < 0.05$) than that detected by CAAX ($48 \pm 9.5\%$, $n = 9$). (**D**) Difference in magnitude of butaprost responses due to AC2-overexpression. 0.3 μ M butaprost responses: MyrPalm, -0.51 ± 2.5 ($n = 11$); CAAX, 1.0 ± 4.0 ($n = 12$). 1 μ M butaprost responses: MyrPalm, 1.0 ± 4.5 ($n = 11$); CAAX, 24 ± 5.7 ($n = 10$). The effect of AC2 overexpression on the response to 1 μ M butaprost detected by CAAX was significantly greater than that detected by MyrPalm ($p < 0.05$). Statistical significance was tested using One Way ANOVA followed by Holm-Sidak method for pairwise multiple comparisons. All responses were normalized to the maximal response elicited by 10 μ M forskolin (FSK) plus 100 μ M IBMX.




Figure 8. Effect of adenylyl cyclase 2 (AC2) overexpression on cAMP responses elicited by β -adrenergic receptor stimulation. Representative time course of changes in the normalized FRET response ($\Delta R/R_0$) detected by Epac2-MyrPalm (MyrPalm) (**A**) and Epac2-CAAX (CAAX) (**B**), following exposure to 1 nM and 3 nM isoproterenol (Iso) in cells overexpressing AC2. **C** Size of average FRET responses in AC2 overexpressing cells. 1 nM Iso: MyrPalm, $16 \pm 5.9\%$ ($n = 5$); CAAX, $11 \pm 3.6\%$ ($n = 3$). 3 nM Iso: MyrPalm, $33 \pm 9.3\%$ ($n = 5$); CAAX, $42 \pm 10\%$ ($n = 3$). **D** Difference in magnitude of Iso responses due to AC2 overexpression. 1 nM Iso: MyrPalm, -6.7 ± 5.4 ($n = 13$); CAAX, -10 ± 7.1 ($n = 11$). 3 nM Iso: MyrPalm, -22 ± 7.0 ($n = 13$); CAAX, -5.1 ± 9.9 ($n = 11$). There was no significant difference in the effects of AC2 overexpression on the responses detected by the different biosensors ($p < 0.05$, One Way ANOVA). All responses were normalized to the maximal response elicited by 1 μM Iso plus 100 μM IBMX.




Figure 9. Compartmentalized cAMP signaling in human airway smooth muscle cells. EP₂ prostaglandin receptor (EP₂R) stimulation of adenylyl cyclase type 2 (AC2) in non-lipid raft domains of the plasma membrane produces cAMP that can be detected by Epac2-CAAX, Epac2-NLS, and Epac2-camps biosensors. β₂ adrenergic receptor (β₂AR) stimulation of adenylyl cyclase type 6 (AC6) in lipid raft domains of the plasma membrane produces cAMP that can be detected by Epac2-MyrPalm, Epac2-camps, Epac2-NLS, as well as Epac2-CAAX biosensors.